Search results
Showing 1 to 15 of 250 results for obesity
This guideline covers the prevention and management of overweight, obesity and central adiposity in children, young people and adults. It brings together and updates all NICE's previous guidelines on overweight and obesity. It does not cover pregnancy.
Show all sections
Sections for NG246
All NICE products on obesity. Includes any guidance and quality standards.
This quality standard covers assessing and managing obesity in adults, young people and children, including referral for specialist care and bariatric (weight loss) surgery. It includes people who are obese and have, or are at risk of, other medical conditions. It describes high-quality care in priority areas for improvement.
View quality statements for QS127Show all sections
Sections for QS127
- Quality statements
- Quality statement 1: Informing people of their BMI
- Quality statement 2: Discussion on the choice of interventions
- Quality statement 3: Referring children and young people for specialist care
- Quality statement 4: Referring adults with type 2 diabetes for bariatric surgery assessment
- Quality statement 5: Referring adults for bariatric surgery assessment
- Quality statement 6: Follow-up care after bariatric surgery
- Quality statement 7: Nutritional monitoring after discharge from the bariatric surgery service
All NICE products on diet, nutrition and obesity. Includes any guidance, advice and quality standards.
Obesity in adults: prevention and lifestyle weight management programmes (QS111)
This quality standard covers preventing adults (aged 18 and over) from becoming overweight or obese. It includes strategies to increase physical activity and promote a healthy diet in the local population. It also covers lifestyle weight management programmes for adults who are overweight or obese. It describes high-quality care in priority areas for improvement.
View quality statements for QS111Show all sections
Sections for QS111
- Quality statements
- Quality statement 1: Vending machines
- Quality statement 2: Nutritional information at the point of choosing food and drink options
- Quality statement 3: Prominent placement of healthy options
- Quality statement 4: Maintaining details of local lifestyle weight management programmes
- Quality statement 5: Publishing performance data on local lifestyle weight management programmes
- Quality statement 6: Raising awareness of lifestyle weight management programmes
- Quality statement 7: Referral to a lifestyle weight management programme for people with comorbidities
Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s (NG202)
This guideline covers the diagnosis and management of obstructive sleep apnoea/hypopnoea syndrome (OSAHS), obesity hypoventilation syndrome (OHS) and chronic obstructive pulmonary disease with OSAHS (COPD–OSAHS overlap syndrome) in people over 16. It aims to improve recognition, investigation and treatment of these related conditions.
Evidence-based recommendations on liraglutide (Saxenda) for managing overweight and obesity alongside a reduced-calorie diet and increased physical activity in adults.
Obesity in children and young people: prevention and lifestyle weight management programmes (QS94)
This quality standard covers preventing children and young people (under 18) from becoming overweight or obese, including strategies to increase physical activity and promote a healthy diet in the local population. It also covers lifestyle weight management programmes for children and young people who are overweight or obese. It describes high-quality care in priority areas for improvement.
View quality statements for QS94Show all sections
Sections for QS94
- Quality statements
- Quality statement 1: Vending machines
- Quality statement 2: Nutritional information at the point of choosing food and drink options
- Quality statement 3: Prominent placement of healthy options
- Quality statement 4: Maintaining details of local lifestyle weight management programmes
- Quality statement 5: Raising awareness of lifestyle weight management programmes
- Quality statement 6: Family involvement in lifestyle weight management programmes
- Quality statement 7: Evaluating lifestyle weight management programmes
Evidence-based recommendations on semaglutide (Wegovy) for managing overweight and obesity in adults.
This indicator covers the establishing and maintaining of a register of patients aged 18 or over with a BMI of 27.5 kg/m2 or more (or 30 kg/m2 or more if ethnicity is recorded as White) in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM222
In development [GID-QS10183] Expected publication date: 05 August 2025
Evidence-based recommendations on tirzepatide (Mounjaro) for managing overweight and obesity in adults.
Naltrexone–bupropion for managing overweight and obesity (TA494)
Evidence-based recommendations on naltrexone–bupropion (Mysimba) for managing overweight and obesity in adults.
Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome (HST31)
Evidence-based recommendations on setmelanotide (Imcivree) for treating obesity and hyperphagia in Bardet-Biedl syndrome in people 6 years and over, only if they are between 6 and 17 years when treatment starts.
Setmelanotide for treating obesity caused by LEPR or POMC deficiency (HST21)
Evidence-based recommendations on setmelanotide (Imcivree) for treating obesity caused by LEPR or POMC deficiency in people 6 years and over.